Melissa R Ferguson, Cassie A Barton, Jesse Bierman, Nathan D Mah, Ran Ran, David Martin, Daniel Hagg and Thomas Deloughery
Objective: To evaluate the efficacy and safety of three different normalization strategies utilizing coagulation factor concentrates (CFCs) in patients with hepatic coagulopathy of either acute or chronic etiology experiencing a life-threatening bleed or need for normalization of coagulopathy prior to invasive procedure.
Design: Retrospective analysis.
Setting: University-affiliated academic medical center.
Patients: Adult patients admitted with hepatic dysfunction who received CFC for treatment of an active bleed or to normalize coagulopathy prior to an invasive procedure.
Interventions: None.
Measurements and main results: Patients were stratified into three treatment groups dependent upon which CFC was administered: recombinant factor VIIa (rfVIIa), three factor prothrombin complex concentrate (3F-PCC)/rfVIIa, or four factor prothrombin complex concentrate (4F-PCC). Fifty patients were included who received rfVIIa (n=19, 38%), 3F-PCC/rfVIIa (n=9, 18%), or 4F-PCC (n=22, 44%) during the study period. The groups were well-matched regarding age, weight, sex, hospital and ICU length of stay, baseline coagulation labs, and characteristics of liver dysfunction. All patients in the rfVIIa and 3F-PCC/rfVIIa groups achieved an INR <1.6 within four hours of first CFC use. Eight patients (36.4%) in the 4F-PCC group met the same endpoint within four hours of administration. Transfusion requirements did not differ before and after CFC administration in all groups. TE complications occurred in eight (16%) patients.
Conclusions: CFCs appear to be effective for the normalization of INR in patients with hepatic coagulopathy in the setting of active bleeding or prior to invasive procedures.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu